Literature DB >> 10384115

A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.

S Matsui1, J D Ahlers, A O Vortmeyer, M Terabe, T Tsukui, D P Carbone, L A Liotta, J A Berzofsky.   

Abstract

Understanding immune mechanisms influencing cancer regression, recurrence, and metastasis may be critical to developing effective immunotherapy. Using a tumor expressing HIV gp160 as a model viral tumor Ag, we found a growth-regression-recurrence pattern, and used this to investigate mechanisms of immunosurveillance. Regression was dependent on CD8 T cells, and recurrent tumors were resistant to CTL, had substantially reduced expression of epitope mRNA, but retained the gp160 gene, MHC, and processing apparatus. Increasing CTL numbers by advance priming with vaccinia virus expressing gp160 prevented only the initial tumor growth but not the later appearance of escape variants. Unexpectedly, CD4 cell depletion protected mice from tumor recurrence, whereas IL-4 knockout mice, deficient in Th2 cells, did not show this protection, and IFN-gamma knockout mice were more susceptible. Purified CD8 T cells from CD4-depleted mice following tumor regression had more IFN-gamma mRNA and lysed tumor cells without stimulation ex vivo, in contrast to CD4-intact mice. Thus, the quality as well as quantity of CD8+ CTL determines the completeness of immunosurveillance and is controlled by CD4 T cells but not solely Th2 cytokines. This model of immunosurveillance may indicate ways to enhance the efficacy of surveillance and improve immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10384115

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis.

Authors:  G Dadaglio; Z Moukrim; R Lo-Man; V Sheshko; P Sebo; C Leclerc
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 2.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

3.  Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.

Authors:  Guoshuai Cao; Jian Wang; Xiaodong Zheng; Haiming Wei; Zhigang Tian; Rui Sun
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

Review 4.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

5.  Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

Authors:  Craig L Slingluff; Gina R Petroni; Walter Olson; Andrea Czarkowski; William W Grosh; Mark Smolkin; Kimberly A Chianese-Bullock; Patrice Y Neese; Donna H Deacon; Carmel Nail; Priscilla Merrill; Robyn Fink; James W Patterson; Patrice K Rehm
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

Review 6.  Ependymomas: development of immunotherapeutic strategies.

Authors:  Ian F Pollack; Regina I Jakacki; Lisa H Butterfield; Hideho Okada
Journal:  Expert Rev Neurother       Date:  2013-10       Impact factor: 4.618

Review 7.  Vaccines targeting helper T cells for cancer immunotherapy.

Authors:  Marit Melssen; Craig L Slingluff
Journal:  Curr Opin Immunol       Date:  2017-07-26       Impact factor: 7.486

8.  Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2.

Authors:  Stefan Fichtner-Feigl; Masaki Terabe; Atsushi Kitani; Cheryl A Young; Ivan Fuss; Edward K Geissler; Hans-Jürgen Schlitt; Jay A Berzofsky; Warren Strober
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 9.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

10.  Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell.

Authors:  Hiroyasu Ito; Mitsuru Seishima
Journal:  J Biomed Biotechnol       Date:  2010-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.